A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 2,196 shares of BIIB stock, worth $345,782. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,196
Previous 1,257 74.7%
Holding current value
$345,782
Previous $291,000 46.05%
% of portfolio
0.01%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$189.07 - $236.8 $177,536 - $222,355
939 Added 74.7%
2,196 $425,000
Q2 2024

Jul 23, 2024

BUY
$190.52 - $236.72 $239,483 - $297,557
1,257 New
1,257 $291,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $22.7B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Wiley Bros. Aintree Capital, LLC Portfolio

Follow Wiley Bros. Aintree Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wiley Bros. Aintree Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wiley Bros. Aintree Capital, LLC with notifications on news.